Broadwood Partners, L.P. bought $10.6M of Oncocyte (OCX)

Executed Feb 6 2025, disclosed Feb 10 2025, 4 days later.

Value, as filed

$10.6M

5,165,695 sh across 2 lots

Executed

Feb 6 2025

the trade date, as filed

Disclosed

Feb 10 2025

4 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

not yet measured

Not yet measured: the 21-session window has not closed, or the prices around it are not on record.

The filer

BP Broadwood Partners, L.P. Director profile →

Broadwood Partners, L.P. (Director) filed 7 Form 4 reports as a reporting entity in the trailing twelve months (7 purchases, 0 sales), most often in STAA. Across 7 priced purchase filings, the average 21-session return was +18.0% from execution and +16.5% from disclosure (delay-adjusted; derived). The largest single filing was $41.1M of STAA (1,500,000 sh across 3 lots, as filed), executed Nov 19 2025.

The name

OCX OCX OCX · 5 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→